| Literature DB >> 30154995 |
J-P Daguer1, C Zambaldo1, M Ciobanu2, P Morieux2, S Barluenga1, N Winssinger1,2.
Abstract
Fragment-based lead discovery has proven to be a powerful method in the drug discovery process. The combinatorial output that is accessible by combining fragments is very attractive; however, identifying fragment pairs that bind synergistically and linking them productively can be challenging. Several technologies have now been established to prepare and screen nucleic acid-encoded libraries (ssDNA, dsDNA, PNA), and it has been shown that pairs of molecules combined by hybridization can bind synergistically to a target. Herein we apply this concept to combinatorially pair two libraries of small molecule fragments, use the fittest fragments supplemented with closely related analogs to build a focused library covalently linking the fragments with different spacers, and apply this strategy to the discovery of a potent ligand for Hsp70.Entities:
Year: 2014 PMID: 30154995 PMCID: PMC6085657 DOI: 10.1039/c4sc01654h
Source DB: PubMed Journal: Chem Sci ISSN: 2041-6520 Impact factor: 9.825
Fig. 1General protocol.
Fig. 2Top: microarray-based screen of combinatorially paired fragments against Hsp70-GST (125 fragment A on the horizontal lines × 500 fragment B on the vertical lines: 62 500 combinations). Bottom: structure of the fragments highlighted on top.
Scheme 1Synthesis of a 10 000-member focused library for Hsp70 (20 A fragments × 5 spacers × 100 B fragments).
Fig. 3Top: microarray-based screen of the focused library under three different conditions: Hsp70-GST, Hsp70-GST + Hsp40, and Hsp70-GST + ATP (blue circles denote the 15 highest intensity compounds). Bottom: structure of the best ligands (blue circles).
SPR affinity measurements of compounds immobilized on a streptavidin chip for the selected ligand. Fluorescence intensities of compounds on the microarray (the mean of four spots with a standard deviation between 5% and 10%)
| Compound | Codons | FU microarray HSP70-GST |
|
|
|
| 6–67 | 28 333 | 5.94 | 563 |
|
| 6–95 | 28 653 | 1.58 | Low binding |
|
| 44–67 | 28 945 | 7.65 | 27 |
|
| 44–28 | 28 566 | 2.69 | 10.7 |
|
| 5–96 | 28 447 | 0.38 | (5.44) |
|
| 74–28 | 28 958 | 2.33 | 18.7 |
|
| 74–89 | 24 143 | 1.34 | (3.17) |
|
| 8–64 | 27 982 | (0.80) | (16.9) |
|
| 8–89 | 29 024 | (0.64) | (14.7) |
|
| 45–64 | 28 961 | 1.88 | 2.97 |
|
| 32–89 | 27 941 | 12.10 | (5.6) |
|
| 4–28 | 28 174 | 2.02 | 10.1 |
|
| 42–27 | 27 215 | (1.16) | (29.5) |
|
| 80–64 | 28 588 | 2.88 | (52.8) |
|
| 72–66 | 28 732 | (1.30) | (35.3) |
χ 2 > 10.
Fig. 4A. Evaluation of the ATPase inhibitor effect of compounds 1b–15b at 200 mM on Hsp70/Hsp40 (1 μM); B. same as in A for compounds 1b and 2b in dose response (0.02–200 molar equivalence).
Fig. 5Affinity pull-down of Hsp70 vs. related (Hsp90) or unrelated (carbonic anhydrase) proteins using streptavidin resin loaded with compound 1a or 2a. A. SDS PAGE (Coomassie affinity Brilliant Blue staining) of supernatant (SN) wash and eluent (E) fractions (biotin was used as a negative control); B. same experiment as in A but with crude cell lysates from HEK and Western blotting using specific monoclonal anti-Hsp70 antibody (carbonic anhydrase was used as a negative control; see Table S1† for MS-MS analysis of the eluent of 2a).